Abstract
Currently, the CHA2DS2-VASc score is the primary tool for assessing thromboembolic risk in patients with atrial fibrillation (AF). However, other potentially relevant clinical variables have not been considered which might...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
